- Home
- RMI vs INMB Comparison
RMI vs INMB Comparison
Compare RMI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMI
- INMB
- Stock Information
- Founded
- RMI 2018
- INMB 2015
- Country
- RMI United States
- INMB United States
- Employees
- RMI N/A
- INMB N/A
- Industry
- RMI Finance/Investors Services
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- RMI Finance
- INMB Health Care
- Exchange
- RMI Nasdaq
- INMB Nasdaq
- Market Cap
- RMI 91.2M
- INMB 68.9M
- IPO Year
- RMI N/A
- INMB 2019
- Fundamental
- Price
- RMI $14.32
- INMB $2.31
- Analyst Decision
- RMI
- INMB Buy
- Analyst Count
- RMI 0
- INMB 4
- Target Price
- RMI N/A
- INMB $9.53
- AVG Volume (30 Days)
- RMI 17.4K
- INMB 6.9M
- Earning Date
- RMI 01-01-0001
- INMB 07-31-2025
- Dividend Yield
- RMI 7.28%
- INMB N/A
- EPS Growth
- RMI N/A
- INMB N/A
- EPS
- RMI N/A
- INMB N/A
- Revenue
- RMI N/A
- INMB $50,000.00
- Revenue This Year
- RMI N/A
- INMB $82.14
- Revenue Next Year
- RMI N/A
- INMB $28,750.98
- P/E Ratio
- RMI N/A
- INMB N/A
- Revenue Growth
- RMI N/A
- INMB N/A
- 52 Week Low
- RMI $13.05
- INMB $1.89
- 52 Week High
- RMI $17.37
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- RMI 48.83
- INMB 26.84
- Support Level
- RMI $14.27
- INMB $2.22
- Resistance Level
- RMI $14.44
- INMB $2.49
- Average True Range (ATR)
- RMI 0.14
- INMB 0.94
- MACD
- RMI 0.01
- INMB -0.24
- Stochastic Oscillator
- RMI 47.38
- INMB 4.31
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.